Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + fluorouracil + lenograstim
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents—cyclophosphamide (an alkylating agent), epirubicin (an anthracycline antibiotic), and fluorouracil (a pyrimidine analog antimetabolite)—together with lenograstim, a recombinant human granulocyte colony-stimulating factor (G-CSF). The CEF or FEC regimen is widely used in the treatment of breast cancer, particularly for node-positive or advanced disease. Cyclophosphamide crosslinks DNA to inhibit cell division; epirubicin intercalates into DNA and inhibits topoisomerase II activity leading to DNA damage; fluorouracil inhibits thymidylate synthase disrupting DNA synthesis. Lenograstim is included as supportive care to stimulate neutrophil production and reduce the risk of chemotherapy-induced neutropenia[1][7]. This combination aims to maximize antitumor efficacy while managing hematologic toxicity.
- Other names
- CEF + lenograstimFEC + lenograstimcyclophosphamide/epirubicin/fluorouracil/lenograstim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)TS (Thymidylate synthase)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + fluorouracil + lenograstim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + fluorouracil + lenograstim.